Brown County Public Health hands out free lead cleaning kits to help families lower exposure risks
GREEN BAY, Wis. (WFRV) – The Brown County Public Health Department handed out free lead cleaning kits to the community on Thursday, in hopes of reducing the exposure risks for young children.
In a Brown County Public Health release, the Department said that children under six years old are at higher risk of exposures, and that even a little dust from old paint could be harmful.
Menasha community & police officers donate new fishing gear to victims of vandalism
Those who live in older homes were especially focused on, specifically due to the risks of old paint, as the free lead kits were handed out at the 'On The Move' Mobile Resource Fair at the Salvation Army from 4 p.m. to 6 p.m.
Each kit provided contained cleaning supplies, step-by-step instructions and information on protecting people from lead poisoning.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
National Alliance on Mental Illness' Brown County office hosts annual mental health picnic
GREEN BAY, Wis. (WFRV) – The National Alliance on Mental Illness (NAMI) Brown County has hosted a picnic at Bay Beach Amusement Park for over 20 years, bringing mental health awareness to the forefront. On Tuesday morning, the annual free community event returned, inviting mental health professionals, local leaders and those battling mental illnesses to gather for food and a day of fun. Wisconsin State Fair releases Cream Puff lineup with chocolate flavor & contests The event included grilled burgers, hot dogs and of course, brats, with plenty of home-baked desserts, as people who live with mental illnesses got a day to relax and enjoy themselves. In addition to the food, the picnic included complimentary ride tickets along with prizes, face painting and more activities for the whole community. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
4 days ago
- Yahoo
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with the exception of resolution n°28 which was rejected in accordance with the recommendations of the Board of Directors. The voting results, resolution by resolution, are available in the Investors & Media section of the Company's website (Shareholders Meeting | GENFIT). ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, G1090N, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor1) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, such as "believe", "potential", "expect", 'target', 'may', 'will', "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website ( and the AMF's website ( and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACT GENFIT | InvestorsTel: +33 3 2016 4000 | investors@ PRESS RELATIONS | MediaStephanie Boyer – Press relations | Tel: +333 2016 4000 | GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | 1 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®. Attachment GENFIT June 17, 2025 Combined Shareholders Meeting ResultsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-06-2025
- Yahoo
HSHS St. Mary's supports nursing staff through in-house, paid certification training
GREEN BAY, Wis. (WFRV) – For over 100 years, HSHS St. Mary's Hospital Medical Center has supported its local talent. In turn, they reinforce their hospital staff. St. Mary runs a Certified Nursing Assistant (CNA) school in-house, offering paid training for employees who want to start a career in health care. Fond du Lac comes together to celebrate Hometown Heroes at Bratfest 'I lead our HSHS St. Mary's CNA school, so it's a certified nursing assistant training program that we hold here in Green Bay at St. Mary's Hospital,' said Clinical Nurse Educator Morgan Wolfgram. 'We teach them the essential skills and provide them with the knowledge to take care of patients within our hospital walls.' The program is structured so that students are hired by the hospital, trained on-site, and placed into jobs on the floor immediately after finishing the course. 'Students are employed and start on the floor, then they transition to a position with St. Mary's CNA school. We teach them and then they transition right back to the floor and have a job right away — so that's one of our perks of the program,' Wolfgram said. Shelby Michaels, a current CNA student, said the program is both intense and rewarding. 'It's been an intense first week, but I've learned a lot,' Michaels said. 'But I've been doing this for the last six years, so it feels like a refresher — but more of an in-depth and very knowledgeable refresher.' What stood out most to her was the hospital's investment in the students. 'They have the CNA school right in-house; they're giving you the opportunity for you to go — paying for it,' Michaels said. 'There's so much opportunity just within this hospital alone that I feel other people should experience.' For Eric Warrichaiet, a CNA who graduated from the program and now works at St. Mary's, the training was a turning point. 'I was looking for a career to make a difference and to help people,' he said. 'So I researched the program, got into the program, and now I'm here.' That support doesn't end after certification. 'They help you sign up to get your state license afterwards, and after that, they give you a follow-up,' Warrichaiet said. 'It's awesome. You have a lot of support. And CNA school — it's not the end. So if you're looking to advance, you have support through that.' Wisconsin State Troopers team up with kids for 'Cops & Bobbers' event in Marquette County As Wisconsin's population ages, the demand for caregivers is only expected to rise. The Wisconsin Hospital Association says residents over 65 make up about 20% of the state's population, but account for about 40% of hospital and clinic visits. That demand is growing faster than the health care workforce can keep up. With St. Mary's celebrating its 125th anniversary this year, Clinical Nurse Educator Morgan Wolfgram says the CNA school is a continuation of a mission that goes back more than a century. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
